Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications
| Autor: | Regan L Asay, Scott D. Beattie, Richard Hoffman, Jillian Venci Fuhs, Jennifer Riddle Camp |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Research program
business.industry United States Food and Drug Administration Advisory committee Communication Internet privacy Filing Public Health Environmental and Occupational Health Pharmacy United States Food and drug administration Pharmaceutical Preparations New chemical entity Biologics License Application Drug Evaluation Pharmacology (medical) business Pharmacology Toxicology and Pharmaceutics (miscellaneous) License New drug application |
| Zdroj: | Therapeutic innovationregulatory science. 55(3) |
| ISSN: | 2168-4804 |
| Popis: | The United States Food and Drug Administration (FDA) implemented the PDUFA V New Molecular Entity (NME) Program (the Program) in 2012 to promote greater transparency and increased communication between the FDA review team and applicants of NME New Drug Applications (NDA) and original Biologics License Applications (BLA). We reviewed 128 publicly available NME NDA and original BLA approval packages, submitted after October 2012 and approved by July 2018. Our research had a goal to educate regulatory professionals about the content and timing of communications from FDA to the Sponsor for approved drugs reviewed under the Program. This research found that communications issued within the first 74 days were consistent with the 21st Century Desk Reference Guide (DRG) targets; forecasted dates of other projected interactions included in the Filing Communication (FC) letter were often within 4 weeks of target. The content and format of the FC letter became more consistent with time, often including templated text. Approximately half the FC letters contained at least 1 filing review issue; however, not all appeared to be substantive. The FDA’s preliminary comment on advisory committee meeting plans were predictive; 95% correlated with the need (or lack thereof) for an advisory committee meeting. Approximately 62% of FC letters contained actionable labeling comments, with nearly all related to editorial changes. With respect to the FC letter, this research found the DRG and relevant FDA Manual of Policies and Procedures to be reliable resources to predict the FDA’s planned actions associated with the filing and review of a NME NDA or original BLA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink